Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology.


Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

Neovii was founded following the acquisition of Fresenius Biotech inheriting more than three decades of experience in specialty pharmaceuticals. Neovii’s global headquarters are located in Rapperswil, Switzerland, its U.S headquarters are in Waltham, MA, and its biologics manufacturing site and German operations are located in Gräfelfing, Germany. Neovii employs approximately 150 employees and has presence in nearly 60 countries worldwide.


For more information about Neovii, click here.